Calcium antagonists and the ischaemic myocardium

Area of Science:

• Cardiology
• Pharmacology
• Physiology

Background:

• Myocardial ischemia and reperfusion can lead to significant catecholamine depletion.
• Noradrenaline (NA) loss from the myocardium during these events may contribute to cardiac dysfunction.
• Calcium (Ca2+) antagonists are known to affect cardiovascular function and cellular processes.

Purpose of the Study:

• To investigate the effect of Ca2+ antagonists on noradrenaline (NA) loss from the myocardium during ischemia and reperfusion.
• To determine if specific Ca2+ antagonists can attenuate or abolish NA depletion under these conditions.

Main Methods:

• Isolated rat hearts (Sprague-Dawley) were perfused and subjected to global ischemia (15 or 60 min) with or without reperfusion.
• Catecholamine levels, specifically noradrenaline (NA), were assayed in the left ventricle.
• Hearts were treated with various Ca2+ antagonists, including verapamil, nifedipine, nitrendipine, nisoldipine, and diltiazem.

Main Results:

• Prolonged aerobic perfusion (90 min) did not cause significant left ventricular NA loss.
• Ischemia (15 or 60 min), especially when followed by reperfusion, resulted in significant NA loss.
• The observed NA loss following 15 min ischemia and reperfusion was abolished or attenuated by verapamil, nifedipine, nitrendipine, nisoldipine, and diltiazem.

Conclusions:

• Ca2+ antagonists effectively reduce or prevent the loss of noradrenaline (NA) from the myocardium during ischemia and reperfusion.
• These findings highlight a potential cardioprotective mechanism of Ca2+ antagonists by preserving myocardial catecholamine stores.
• The study suggests that Ca2+ channel blockade may mitigate cardiac damage associated with ischemic events.